Patents by Inventor Michelle Brenda Pires

Michelle Brenda Pires has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR)
    Publication number: 20240084252
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Application
    Filed: November 8, 2023
    Publication date: March 14, 2024
    Applicant: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
    Patent number: 11851680
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Grant
    Filed: August 17, 2022
    Date of Patent: December 26, 2023
    Assignee: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR)
    Publication number: 20230279349
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Application
    Filed: August 17, 2022
    Publication date: September 7, 2023
    Applicant: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
    Patent number: 11453861
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Grant
    Filed: March 14, 2022
    Date of Patent: September 27, 2022
    Assignee: PRECISION BIOSCIENCES, INC.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR)
    Publication number: 20220204929
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Application
    Filed: March 14, 2022
    Publication date: June 30, 2022
    Applicant: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR)
    Publication number: 20210254002
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Application
    Filed: April 8, 2021
    Publication date: August 19, 2021
    Applicant: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
    Patent number: 11008548
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Grant
    Filed: June 22, 2020
    Date of Patent: May 18, 2021
    Assignee: PRECISION BIOSCIENCES, INC.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires
  • GENETICALLY-MODIFIED IMMUNE CELLS COMPRISING A MICRORNA-ADAPTED SHRNA (SHRNAMIR)
    Publication number: 20200370014
    Abstract: The present invention encompasses genetically-modified immune cells (and populations thereof) expressing a microRNA-adapted shRNA (shRNAmiR) that reduces the expression of a target endogenous protein. Methods for reducing the expression of an endogenous protein in an immune cell are also provided wherein the method comprises introducing a shRNAmiR that targets the endogenous protein. Using shRNAmiRs for knocking down the expression of a target protein allows for stable knockdown of expression of endogenous proteins in immune cells.
    Type: Application
    Filed: June 22, 2020
    Publication date: November 26, 2020
    Applicant: Precision Biosciences, Inc.
    Inventors: Aaron Martin, Jon E. Chatterton, Michelle Brenda Pires